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Abstract: It is known that extracellular vesicles (EVs) are shed from cells of almost every type of
cell or organism, showing their ubiquity in all empires of life. EVs are defined as naturally released
particles from cells, delimited by a lipid bilayer, and cannot replicate. These nano- to micrometer
scaled spheres shuttle a set of bioactive molecules. EVs are of great interest as vehicles for drug
targeting and in fundamental biological research, but in vitro culture of animal cells usually achieves
only small yields. The exploration of other biological kingdoms promises comprehensive knowledge
on EVs broadening the opportunities for basic understanding and therapeutic use. Thus, plants might
be sustainable biofactories producing nontoxic and highly specific nanovectors, whereas bacterial
and fungal EVs are promising vaccines for the prevention of infectious diseases. Importantly, EVs
from different eukaryotic and prokaryotic kingdoms are involved in many processes including
host-pathogen interactions, spreading of resistances, and plant diseases. More extensive knowledge
of inter-species and interkingdom regulation could provide advantages for preventing and treating
pests and pathogens. In this review, we present a comprehensive overview of EVs derived from
eukaryota and prokaryota and we discuss how better understanding of their intercommunication
role provides opportunities for both fundamental and applied biology.
Keywords: extracellular vesicles; prokaryota; eukaryota; archaea; interkingdom communication;
cross-kingdom RNAi
1. Introduction
Currently, it is well-known that extracellular vesicles (EVs) play a role in diverse cellular
communication processes. Initially, when they were discovered, no function could be identified.
As shown in the timeline (Figure 1), the first observation of multivesicular bodies (MVBs), and thus of
(intraluminal) exosomes which are the smallest class among EVs, occurred in the 1950s. MVBs were
first recognized in algae [1] and mammalian cells [2]. At the same time, outer membrane vesicles
(OMVs) were found in bacteria [3,4]. Nearly ten years after the detection in algae, in 1965, MVBs
were found in higher plants [5]. Again, after almost a decade, in 1973, EVs were reported in fungi [6].
At that time, probably none of the researchers recognized the significance of the discovered structures.
About two decades later, by investigating reticulocytes, exosomes were thought to facilitate cells getting
rid of garbage. It was assumed that they simply “defenestrate” remnants, instead of degradation [7–10].
This assumption of waste disposal probably resulted from the juvenile state of research on EVs at that
time. The year 1996 marked a turning point in the thinking of EVs, when Raposo et al. assumed EVs
influenced antigen presentation in vivo [11]. Since then, EVs were no longer thought to function only
as “trash cans”.
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Figure 1. Timeline of extracellular vesicle (EV) research throughout all empires. First recognized, in 
the late 1950s, EVs have been found throughout all empires of life. Although they were initially 
underestimated as “trash cans”, diverse functions, as well as clinical applications, have been 
identified, such as their role as RNA transporters or their clinical use in regenerative medicine. ISEV, 
International Society for Extracellular Vesicles; MISEV, minimal information for studies of 
extracellular vesicles; MSC, mesenchymal stem cell; MVB, multi vesicular body; OMV, outer 
membrane vesicle; and sRNA, small noncoding RNA. 
The ubiquity of EVs in all empires of life was confirmed in 2000, when they were accounted for 
in archaea [12]. In recent years, much knowledge on EVs has been gathered. Loaded with bioactive 
proteins, lipids, and nucleic acids, EVs enable long distance communication between cells. 
Information can either be transmitted by EV uptake (membrane fusion, endocytosis) into the recipient 
cell or via receptor interaction on the cell surface [13,14]. Because EVs shuttle nucleic acids, they 
facilitate post-transcriptional regulation of the recipient cell metabolism. It was revealed, in 2007, that 
EVs carry messenger RNA (mRNA) and small noncoding RNA (sRNA), enabling cells to exchange 
genetic information, and therefore the thinking of intercellular communication was renewed [15–18]. 
The key regulators are sRNAs, a class of single stranded RNA, comprising around 22 nucleotides. 
This sRNA binds complimentarily to mRNA, resulting in post-transcriptional gene silencing [19–21]. 
EVs protect this fragile cargo from degradation by RNases and appear to be responsible for targeting 
recipient cells [20,22–28]. Compared to cell-cell communication, utilized by low-molecular messenger 
substances (e.g., hormones), EVs further provide vehicles transmitting cargo in high concentrations, 
unaffected by diffusion or dilution [29]. 
EVs were observed throughout all empires of life, underlining their high evolutionary 
importance, however, to date, the major question about EVs remains unanswered, i.e., "What is their 
elementary function?” Although we cannot solve this conundrum, in this review, we have compiled 
information on EVs from different origins and vesicular cross talk between individuals, species, and 
even kingdoms. 
2. Eukaryotic EVs 
2.1. Animal EVs 
EVs have been isolated from almost all types of mammalian cells or body fluids. Three main 
groups are widely accepted apoptotic bodies, microvesicles, and exosomes [30,31]. Apoptotic bodies 
(1000 to 5000 nm in diameter) result from cell fragmentation and budding. They occur as a product 
of programmed cell death to be phagocytosed. Microvesicles (100 to 1000 nm), also called 
microparticles, are shed directly by plasma membrane, while exosomes (30 to 150 nm) are released 
by fusion of MVBs with the plasma membrane [10,27,28,32,33]. Specific markers of EV subtypes are 
not yet universally accepted. Thus, the International Society for Extracellular Vesicles (ISEV) suggests 
the use of innocuous terms, referring to physical or biochemical characteristics, isolation conditions, 
or cell origin such as small EVs, tetraspanin CD9+ EVs, or macrophage derived EVs. The minimal 
information for studies of extracellular vesicles (MISEV) guidelines, published in 2014 and 2018, 
further define requirements for EV isolation, characterization, and quantification which researchers 
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in the late 1950s, EVs have been found throughout all empires of life. Although they were initially
underestimated as “trash cans”, diverse functions, as well as clinical applications, have been identified,
such as their role as RNA transporters or their clinical use in regenerative medicine. ISEV, International
Society for Extracellular Vesicles; MISEV, minimal information for studies of extracellular vesicles;
MSC, mesenchymal stem cell; MVB, multi vesicular body; OMV, outer membrane vesicle; and sRNA,
small noncoding RNA.
The ubiquity of EVs in all empires of life was confirmed in 2000, when they were accounted for
in archaea [12]. In recent years, much knowledge on EVs has been gathered. Loaded with bioactive
proteins, lipids, and nucleic acids, EVs enable long distance communication between cells. Information
can either be transmitted by EV uptake (membrane fusion, endocytosis) into the recipient cell or
via receptor interaction on the cell surface [13,14]. Because EVs shuttle nucleic acids, they facilitate
post-transcriptional regulation of the recipient cell metabolism. It was revealed, in 2007, that EVs
carry messenger RNA (mRNA) and small noncoding RNA (sRNA), enabling cells to exchange genetic
information, and therefore the thinking of intercellular communication was renewed [15–18]. The key
regulators are sRNAs, a class of single stranded RNA, comprising around 22 nucleotides. This sRNA
binds complimentarily to mRNA, resulting in post-transcriptional gene silencing [19–21]. EVs protect
this fragile cargo from degradation by RNases and appear to be responsible for targeting recipient
cells [20,22–28]. Compared to cell-cell communication, utilized by low-molecular messenger substances
(e.g., hormones), EVs further provide vehicles transmitting cargo in high concentrations, unaffected by
diffusion or dilution [29].
EVs were observed throughout all empires of life, underlining their high evolutionary importance,
however, to date, the major question about EVs remains unanswered, i.e., "What is their elementary
function?” Although we cannot solve this conundrum, in this review, we have compiled information on
EVs from different origins and vesicular cross talk between individuals, species, and even kingdoms.
2. Eukaryotic EVs
2.1. Animal s
EVs have been isolated from almost all types of mammalian cells or body fluids. Three main
groups are widely accepted apoptotic bodies, microvesicles, and exosomes [30,31]. Apoptotic bodies
(1000 to 5000 nm in diameter) result from cell fragmentation and budding. They occur as a product of
programmed cell death to be phagocytosed. Microvesicles (100 to 1000 nm), also called microparticles,
are shed directly by plasma membrane, while exosomes (30 to 150 nm) are released by fusion of MVBs
with the plasma membrane [10,27,28,32,33]. Specific markers of EV subtypes are not yet universally
accepted. Thus, the International Society for Extracellular Vesicles (ISEV) suggests the use of innocuous
terms, referring to physical or biochemical characteristics, isolation conditions, or cell origin such as
small EVs, tetraspanin CD9+ EVs, or macrophage derived EVs. The minimal information for studies of
extracellular vesicles (MISEV) guidelines, published in 2014 and 2018, further define requirements for
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EV isolation, characterization, and quantification which researchers should respect when working with
EVs, and therefore provide useful evaluations and recommendations of techniques and devices [34,35].
Analytic marker proteins, both localized on the membrane surface and in the vesicular matrix, are well
described [34–36], especially the transmembrane tetraspanins CD9, CD63, and CD81 which are often
used as markers, as well as for EV isolation and purification [32,37–40]. These and other markers are
widely, but not generally accepted [35]. More extensive information regarding, especially, human EVs
has been compiled in a couple of comprehensive reviews [13,16,31,33,41,42].
2.1.1. EVs in Health and Diseases
EVs can apparently influence health. This is particularly reflected when physiological processes
turn pathological. Disorders and stress can alter EV secretion, as neurodegenerative diseases such as
Alzheimer’s and Parkinson´s disease, multiple sclerosis, amyotrophic lateral sclerosis, and strokes can
cause changes to EV release. It remains to be clarified whether EVs have detrimental or protective effects
on the progression of neurodegenerative diseases [43–45]. Although our knowledge of how EVs are
involved into the pathology of certain diseases needs to be expanded, we can utilize them as biomarkers.
For instance, several cancer types can be detected, even in early stages [45]. Apparently, EVs play
a crucial role concerning infectious diseases. They elicit a bidirectional arms race in host–pathogen
interaction (see also Section 4 Interindividual, Interspecies, and Inter-Kingdom Regulation). In order
to stimulate the immune response, the infected cells send EVs, loaded with pathogen-associated
molecular patterns (PAMPs) [46]. The list of human diseases, influenced by EVs, is constantly growing.
Autoimmune disorders [47] are affected, as well as diseases of aﬄuence, for example, atherosclerosis,
obesity, and metabolic syndrome. Obesity and atherosclerosis have been shown to be associated with
elevated EV numbers and altered composition [14]. In obese patients, adipocyte-derived exosomes
could increase oxidative stress and progression of chronic inflammation [48].
Of particular interest is the EV linkage between human health and diseases in the field of cancer
treatment. On the one hand, EVs derived from dendritic cells have been shown to suppress murine
tumor growth [49]. On the other hand, exosomes are involved in multiple therapeutically difficult cancer
processes, such as tumor growth, tumorigenesis, angiogenesis, drug resistance, and metastasis [50–52].
These controversial facts lead to the conclusion that exosomal cell-to-cell communication in cancer is a
bidirectional signaling pathway (Figure 2). One major topic in the current research on mammalian
exosomes is whether they can be used to advance cancer therapy [53,54]. Nevertheless, EVs are
promising biomarkers for distinct medicinal diagnostic purposes such as early and precise detection
of several cancer types, infectious diseases, diabetes, autoimmune disorders, and neurodegenerative
diseases [14,45,50,55–57].
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Figure 2. Bidirectional regulation of cancer via extracellular vesicles (EVs). Vesicular regulation can
come to pass in both directions. Cancer cells can be affected positively by EVs from healthy cells,
leading to tumor apoptosis or at least inhibition of progress. Meanwhile, EVs derived from cancer cells
can also stimulate cancerogenesis or metastasis either in the microenvironment of the originating cell
or in distant tissues. Additionally, EVs can be used as diagnostic tools, as well as therapeutic vehicles.
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2.1.2. Therapeutic Applications of Mammalian EVs
In the field of EV-based therapeutics there are a few successful preclinical concepts that underline
the potential of these natural nanoparticles. There are two main areas of interest for EV-therapeutics
which are:
• their use in regenerative medicine;
• EVs as carriers for drugs.
In several studies, EVs from mesenchymal stem cells (MSCs) have been shown to have an
inherent anti-inflammatory and immunomodulatory capacity [58] and may positively influence tissue
regeneration after cardiac injury [59]. Since this finding, many preclinical assessments have used MSC
EVs for repair of liver [60] and myocardial tissue [61]. An important example of the anti-inflammatory
and immunomodulatory potential of MSC EVs was reported, in 2014, by Kordelas et al. [62].
They showed that life-threatening immune overreaction due to the graft-versus-host phenomenon
could be ameliorated by sequential application of MSC EVs. Among the different potential therapeutic
applications of EVs, the use of anti-inflammatory MSC EVs appears to be most advanced and it
is important to find suitable regulatory guidelines for their production under good manufacturing
practice conditions [45,63].
Especially in cancer therapy, nanoscale drug encapsulation is a quickly developing field. One major
advantage of such approaches is that doses can be reduced due to increased bioavailability, leading to
diminished toxicity of cytostatic agents. The number of semi- and synthetic nano-formulations is high,
while only a few EV preparations are being investigated clinically [64].
Regarding the use of EVs as drug carriers, there appear to be a few important challenges to overcome
when these approaches are to be tested preclinically. These challenges include EV-heterogeneity and
characterization of EV population used and their reproducible production and loading with compounds
of choice. Various loading methods are described in the literature, including passive incubation,
saponin-assisted encapsulation, electroporation, ultrasound, and extrusion [65,66]. The efficiency
of each of these methods appears to be highly dependent on the cellular source of EV and the
physicochemical properties of encapsulated drugs. Moreover, specific pharmacokinetic properties
of EVs, such as circulation kinetics and biodistribution profile [67], are not as understood as needed.
For a detailed overview on these topics, the reader is referred to recent review manuscripts [65,68].
These manuscripts underline that the field of EV-therapeutics is already on the right track, but additional
effort is needed to better clarify which physiological behavior EVs have when used as therapeutics,
and which biological barriers they encounter when administered systemically [69].
Interestingly, the US Food and Drug Administration has recently approved the first RNA
interference-based drug. As the active compound, siRNA is carried by lipid nanoparticles and intended
to treat hereditary transthyretin amyloidosis. The nanoparticles prevent RNA degradation and facilitate
entry into cells, which is exactly the same role that EVs are thought to have, however, these nanoparticles
have limitations since they can show dose-limiting toxicity and their target is nearly exclusively the
liver [68]. Liposomal formulations have been investigated since the 1960s, and thus they are probably
the best investigated group in nanomedicine. Although modification can improve liposome properties,
such difficulties have not yet been overcome satisfyingly [70–72]. Furthermore, it is noteworthy that in
the tremendous list of organic nanomaterials, compiled by Palazzolo et al., there is only one single
preparation that is applied orally, i.e., grape exosome-like nanoparticles loaded with curcumin [64].
Apparently, EVs (also from others than the animal kingdom) have underestimated properties.
Presently, sufficient amounts of EV production is a limiting aspect for therapeutic usage. Depending
on the cultured cell type, yield can vary significantly. For example, 785 µg EVs have been isolated
per million B16BL6 cells while one million MKN45 cells delivered 375 µg EVs after 72 h incubation,
indicating that EV release is cell-type and incubation-time dependent [73,74]. Different approaches
could be adopted to enhance the outcome, such as:
• stimulation of EV production [73,75,76];
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• using bioreactors which can increase EV yields more than 100-fold as compared to conventional
cell cultures [74];
• exploration of alternative EV sources.
Alternative sources for EV production can predictively be either animals (e.g., bovine milk [77])
or plants. Fungal and prokaryotic EVs appear to be inappropriate due to immunogenic properties
(see below).
2.1.3. External Factors Influencing EV Homeostasis
In recent years, it has been demonstrated that plant secondary metabolites have effects on exosomal
sRNA and EV levels in mammals. Recently, an overview has been given by Otsuka et al. [18]. More and
more evidence suggests that food-derived EVs can influence human health. Since circulating sRNAs in
body fluids can regulate metabolism and mRNA translation in the whole organism, it is conceivable that
food-derived sRNAs, shuttled by EVs, spread their effects throughout the body [18,28]. It is still difficult
to interpret how food-derived EVs or their cargo pass the intestinal barrier, since both membrane fusion
and endocytosis are possible uptake mechanisms. How EV cargo is shuttled through or processed
inside the enterocyte remains questionable, as schematically shown (Figure 3). Because the human diet
usually consists of plants as a major component, plant EVs apparently have a comprehensive influence
on human metabolism and on gut microbiota [78].
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Figure 3. Intestinal resorption, processing, and release of extracellular vesicles (EVs). EVs can be
absorbed by enterocytes via membrane fusion or endocytosis mechanisms. It remains ambiguous if food
derived EVs can pass the intestinal barrier unprocessed, or if they induce changes inside the enterocyte,
and therefore influence the cargo and release of enterocyte derived EVs. MVB, multivesicular body;
sRNA, small noncoding RNA; MV, microvesicle.
2.2. Plant EVs
“Exosome-like” EV populations have been found in distinct plants. EVs have been isolated from
diverse organs like leaves, fruits, seeds, roots/rhizoma, pollen or semen [18,79–84], leading to the
conclusion that EVs are in plants as ubiquitous as they are in animals.
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Plant-derived EVs showed median diameters of ~400 nm for EVs from grapes, and ~250 nm
for edible grapefruit and ginger nanoparticles. While both small (~100 nm) and large (~1000 nm)
EVs were found in carrots [81,85]. Recent investigations of four Citrus L. species, by Pocsfalvi et al.,
have also shown small and large EV populations with significant differences in particle sizes and yields
between the species, although they all belong to the same genus. The group divided between micro-
and nano-vesicle fractions. Combined yields were determined as follows: grapefruit delivered 6.1 mg
vesicle protein/mL fruit juice, orange 3.5 mg/mL, bitter orange 1.3 mg/mL, and lemon 0.8 mg/mL [86].
These data indicate that plants release EVs with species-specific sizing. The amounts of vesicles that
are shed can probably be induced by external factors such as pathogen infection [27]. The influence of
the size on particle properties cannot be overseen at this state of knowledge.
Observing plant EVs being shed from MVBs by electron microscopy [84] has proven that plants
indeed shed genuine exosomes. Supporting evidence is delivered by the comparatively high similarity
between the proteomes of EVs and MVBs/late endosomes [27]. Nonetheless, we have no information
on plant-derived microvesicles and, so far, can only divide into small and large EVs or nano- and
microvesicles, which is sufficient until more information is available. Furthermore, depending on
the isolation technique, the vesicle´s origin can be ambiguous and EVs can be accompanied by
intracellular vesicles.
The cell wall appears to be a barrier that cannot be overcome by EVs, but it only seems as such,
because EVs can indeed be isolated from apoplastic fluids [27,79,87]. The hypotheses on how EVs pass
cell walls, can assumedly be transferred from bacteria and fungi to plants. These are that EVs can be
forced mechanically through the walls, because the membrane is not rigid, or that the wall thickness,
integrity, or pore size is adapted to EV release. Another theory is that the EVs temporarily loosen the
wall structure, since cell wall remodeling enzymes have been found in EV preparations [29,88–92].
Walker et al. demonstrated 60 nm to 80 nm liposomes penetrating the fungal cell wall, having a
predicted pore size of approximately 5.8 nm. The group concluded that cell walls are less rigid than
they are usually assumed to be. They are rather dynamic structures with flexible viscoelastic properties
and permissiveness for vesicular structures in both directions, i.e., uptake and release [93].
2.2.1. Plant EV Lipids
Lipidomic analysis of plant EVs has revealed a relatively unusual range of lipid compounds.
Comparative TLC lipid profiling of EVs, isolated from grape, grapefruit, ginger, and carrot, has
shown some characteristic bands for all species. The organ of origin also influenced the lipid
profile [81]. EVs isolated from grapefruits (Vitis vinifera L.) were found to comprise 98% phospholipids
(amongst them mainly phosphatidic acid (PA) with approximately 50%) and only 2% typical
plant galactolipids. PA was shown to be mitogenic, as well as controlling membrane fusion
and fission processes [80,85,94,95]. A study on grapefruit-derived EVs indicated an enrichment
of phosphatidylethanolamine (45%) and phosphatidylcholine (28%), whereas PA was only slightly
present with an amount of 2.5% [96]. Ginger EV lipids mainly consist of PA (~43%) and mono- and
digalactosyldiacylglycerol (~46%) [72,95].
Membrane lipids are obviously determining EV stability. Differences in lipidomic profiles
are possibly crucial for targeting certain recipients and might form the basis for interspecies and
inter-kingdom communication. One can hypothesize that plants release EVs with different membrane
composition to address different targets. This would, of course, not only affect lipids, but also cargo
and proteome.
2.2.2. Proteins of Plant EVs
The lack of protein markers for plant EV definition, determination, and isolation created increasing
interest in their proteomic profile. Some proteins or protein families have been detected from
independent groups in distinct plant species, such as patellins 1–3 [27,86], tetraspanin 8 [27,97], clathrin
heavy chain [27,80,86,98], and heat shock proteins [27,80,86,96,98].
Int. J. Mol. Sci. 2019, 20, 5695 7 of 26
We have compiled frequently identified EV proteins (Table 1) which were isolated from distinct
plant species. Future plant EV markers are probably among them.
Table 1. Proteins and protein families found repeatedly in plant EVs.













PIP 1-3, 2-2, 2-4 [80]




Clathrin heavy chain * [91,98]
Clathrin heavy chain 1 *, 2 * [27,86]
Coatomer Coatomer subunits alpha, beta, gamma, delta,epsilon and isoforms [86,98]
Heat shock proteins
Heat shock protein 90 * [86,91,96,98]
Heat shock 70 kDa protein 3, 5- like, 14-like [27,86]
Heat shock protein 70 * [82,91,98]
Heat shock cognate 70 kDa protein 1 * [27,80]
Patellins
Patellin 1 *, 2 * [27]






Rab-2A, 5C, 6A, 7A, 8A, 11A, 18 [98]
Syntaxins
(GFP-) Penetration 1 *
Synaptotagmin A [27]
Synaptobrevin homolog
Syntaxin of plants 5
Novel plant SNARE
[98]
Vesicle transport v-SNARE 11, 13 [27,86]
others
CHMPs 1, 4, 6
ESCRT-I complex subunits TSG101, VPS28, VPS37
Vesicle-associated membrane proteins 7, 72
[98]
Tetraspanin 8 *, 9, 18 [27,97]
Vesicle-associated protein 4-1 [27]
CHMP, charged multivesicular body proteins; ESCRT, endosomal sorting complexes required for transport; PIP,
plasma membrane intrinsic proteins; (v-) SNARE, (vesicle) soluble N-ethylmaleimide-sensitive-factor attachment
receptor; TIP, tonoplast intrinsic proteins; and TSG, tumor susceptibility gene, * Proteins of particular interest.
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2.2.3. Applications of Plant EVs
Recently, upcoming evidence has shown that plant miRNAs and EVs are promising agents for
therapeutic use. For example, grape EVs have shown beneficial effects on mouse intestine regeneration.
Vesicles effectively induced proliferation of murine intestinal stem cells, when administered under
pathological conditions. Mucosal epithelium regeneration was accelerated and the intestinal
architecture rapidly restored throughout the entire length of the intestine [80]. Significantly, continuous
oral administration protected mice from dextran sulfate sodium-induced colitis and treated mice
lived twice as long as untreated mice [80,99]. Additionally, it has been shown that ginger-derived
EVs are preferentially taken up by intestinal macrophages or monocytes, and therefore induce
anti-inflammatory mediators. Dietary uptake of EVs from distinct fruits and vegetables probably
provides greater beneficial effects for the maintenance of gut homeostasis than from single plant
EVs [81]. Oral administration of ginger EVs protected mice from alcohol-induced liver injury, suggesting
promising properties as a novel agent to prevent or even cure liver damage [100]. Nanosized vesicles
isolated from Citrus limon (L.) Osbeck inhibited cancer cell growth in vitro and in vivo. It is remarkable
that normal cells were not affected and angiogenesis was also inhibited [98]. This underlines the
capability of inter-kingdom regulation through food-derived EVs and their potential as therapeutic
vehicles. For this purpose, nanovectors were made of lipids, isolated from either grapefruit or ginger
EVs. These nanovectors have shown several properties of major pharmaceutical interest, such as:
• no cytotoxic effects [71,72];
• higher uptake efficiency for the majority of investigated cells (even B and T cells), compared to
liposomal formulation [71];
• no immune reaction detectable [71];
• no observable adverse effects [101];
• intranasal nanovector application delivered miR-17 to brain tumor cells within a short time in
mice, whereas liposomes did not reach the brain [101];
• intravenous injection of nanovectors delivered miR-18a to liver macrophages and, consequently,
promoted anti-tumor M1 macrophage induction [102];
• highly efficient cell internalization and cancer suppression of aptamer-doxorubicin loaded
nanovectors [103]
Crucial advantages of EV packaged drugs have been revealed, such as increased stability, solubility,
and bioavailability of hydrophobic agents, whereas no altering of the drug´s biological activity was
recognized. Regarding biocompatibility and biodegradability, EVs offer sustainable materials [71],
which can be harvested in large scale from plants and prospectively used for clinical applications in a
highly safe and cost-efficient manner [95,102,104]. The findings on differing lipid profiles between plant
EVs, together with the data on in vitro and in vivo effects lead us to the assumption that nanovectors
could be specifically targeted by combining different plant EV derived lipids.
EVs from Helianthus annuus L. inhibited fungal spore germination, mycelial growth, and loss of
vitality [91]. Furthermore, EVs appear to be enriched by plants in response to fungal infections [27,91,97]
and antifungal Shogaol has been determined in ginger-derived EVs [100,105]. Combined, these data
indicate that plants shed EVs into the apoplastic space as a kind of functional patrol unit, providing
protection from fungal invaders. We can potentially use these antifungal properties of EVs in therapy
of topical and systemic mycoses. An extended knowledge of EVs and the mechanisms of information
transportation also provides a chance to control fungal plant pests, which can cost severe losses in
cultivation of food plants, without toxicity for the environment, humans, and animals [106].
2.3. Fungal EVs
Although the first observations of fungal EVs were in the early 1970s, interest in them declined, to a
30-year slumber, and was reawaken in the beginning of the 21st century [6,107–109]. Fungal EV protein
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composition and morphology show similarities with mammalian exosomes [29]. Possibly, fungal
EVs originate from membrane budding [110] or from cytosolic compartments [111]. EV formation in
fungi has not been conclusively clarified, but it seems as if they release MVB-derived exosomes and
membrane-derived microvesicles, similarly to animal cells [90,109,112,113].
As in plants, the passage of fungal EVs through the cell wall remains a mysterious, keeping
scientists on tenterhooks, whereas hypotheses were adopted from one kingdom to another (see also
Section 2.2 Plant EVs). Fungal EVs comprise RNA species, such as mRNA, tRNA, and sRNA, and
protect them from RNase degradation [114], comparable with animal and plant EVs. Thus, fungal EVs
are capable of cell-to-cell communication and inter-kingdom regulation [115,116]. It is assumed that EVs
are strongly correlated to fungal virulence [90,108,117–119], since different mutants, with impaired EV
secretion capability, showed less pathogenicity [120–122] and co-application of Cryptococcus neoformans
(San Felice) Vuill. with additional EVs elevated fungal infectivity [123]. Unlike plant EVs, EVs from
fungi can provoke an immune response, when administered in vivo. Thus, clinical use of fungal EVs
offers potential vaccines against mycoses [90,118,119]. Fungal EVs have stimulated the release of the
cytokines IL-4 and TNF-α in vivo [124], as well as nitric oxide, IL-10, IL-12 TNF-α, and fungicidal
activity of macrophages in vitro [114,119,125].
Fungal EV Proteins and Lipids
Since fungal EV lipidomic and proteomic data have already been compiled [109,113], we want to
point out some especially interesting facts, such as detected homologous proteins, which we estimated
to be of particular interest in plant EVs. As such, clathrin heavy chain, heat shock proteins, syntaxins,
and ESCRT complexes were identified in Malassezia sympodialis R. B. Simmons et E. GuÉho [126].
In addition to other proteins, heat shock proteins were found throughout many species, such as in
Candida albicans (C. P. Robin) Berkhout [119], Histoplasma capsulatum Darling [117], Paracoccidioides
brasiliensis (Splend.) F. P. Almeida [127], and Saccharomyces cerevisiae (Desm.) Meyen [128].
More remarkable are the results of lipid analysis, since phospholipids also appear in fungal
EVs [113]. They were found in sterols, as well as in the neutral glycosphingolipid glucosylceramide in
C. albicans [119], H. capsulatum [117], and P. brasiliensis [129]. The identification of glucosylceramide
among EV lipids is of particular significance, due to the findings that C. neoformans loses its virulence,
when lacking glucosylceramide synthase [130], and that it is essential for hyphal growth and
spore germination for instance in Aspergillus nidulans (Eidam) G. Winter and Fusarium graminearum
Schwabe [131,132]. Consequently, EVs appear to be substantially involved in fungal virulence and not
merely the cargo but also the shell is decisive for EV functionality.
3. Prokaryotic EVs
3.1. Bacterial EVs
Sixty years ago, it was observed that cell-free supernatants of extracellular lipid-dense material
from pathogenic Vibrio cholera Pacini culture contained parts of the bacterial outer membrane material
with toxic effects on human cells [3]. Electron microscopy imaging revealed nanometer-sized droplets,
which were budding from the bacterial cell wall [4]. These droplets are now known to be OMVs,
a subcategory of EVs. In a stricter definition, only vesicles secreted from gram-negative bacteria are
termed OMVs, whereas those from gram-positive bacteria are called microvesicles, however, the term
OMV is now widely used.
All gram-negative and some gram-positive bacteria constitutively release OMVs, ranging in
size from 20 nm to 250 nm in diameter, into the extracellular milieu [89,133]. The structure of
OMVs is closely connected to the architecture of the (gram-negative) cell envelope. In general,
OMVs are composed of an outer leaflet of lipopolysaccharide and an inner leaflet of phospholipid,
decorated with membrane and surface proteins, and, as compared with human EVs, they additionally
possess other structural features [134]. Indeed, OMVs have been shown to contain all sorts of cargos
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including cell wall components, peptidoglycans, outer membrane proteins, lipopolysaccharides,
phospholipids, as well as soluble proteins (periplasmic, cytoplasmic) such as enzymes, nucleic acids
(DNA, RNA) [135,136] and secondary metabolites [137]. OMVs are temperature and chemically stable
entities [138]. Their composition, yield, and content can differ based on bacterial source and general
growth conditions, such as nutrients, temperature, antibiotics, etc. [139]. Interestingly, even in the
same culture under similar conditions, subpopulations of OMVs with different properties can be
identified [139], a puzzling phenomenon that is still under discussion.
3.1.1. Biogenesis of OMVs
Under natural conditions OMVs are produced rather passively as side products of cellular
processes, but they may also be shed in response to stress, via explosive cell lysis [140], or in an active
manner [141]. The exact mechanism which results in outer membrane budding remains unknown,
and the following three models for OMV biogenesis are currently discussed:
• random budding during cell wall turnover;
• the stress response model;
• structural changes of lipopolysaccharides.
Cell wall turnover is a natural routine process in which the cell recycles cell wall components such
as peptidoglycans. For this, the lipoprotein links between the outer membrane and the peptidoglycans
have to be cut and rearranged leading to membrane protrusion and vesicles release from the
cells surface into the extracellular space [142]. The stress response model is based on physical
or chemical stress-induced malfunctioning membranes leading to accumulation of peptidoglycan
fragments or misfolded proteins in the periplasm [143]. This leads to enhanced turgor pressure,
membrane protuberances, and pinching-off of small membrane portions. This model supports
the idea of OMV formation as a helpful waste mechanism to get rid of excess potentially harmful
proteins [141]. Another model postulates that cations that cross-bridge the highly electronegative
lipopolysaccharides, induce structural changes. Subsequent repulsion between lipopolysaccharides
leads to local deformation and bacterial cell membrane shedding [144,145]. OMV production is a
resource-depleting process, which probably would not be favored by evolution, if it was not for a
purpose. Therefore, no models alone can comprehensively illuminate OMV production under natural
conditions. Proteome analysis showed that OMV content could be enriched or depleted in comparison
to the originating bacterial envelope fractions, indicating that OMV and outer membrane profiles are
not necessarily identical [141] and that specific cargo can be actively sorted into OMVs. One model of
active sorting is based on the discovery that the OMV production is not uniformly distributed along
the outer membrane but concentrates on distinct areas or “hot spots” [133]. These hot spots were found
to be locally enriched with specific proteins and lipids, while other vesiculation inhibiting proteins,
such as lipoproteins for cell wall integrity, were reduced [144]. Some of the proteins involved in
hyper- or hypovesiculation were identified by deleting genes potentially involved in OMV production,
but direct evidence for active OMV biogenesis is still lacking. Most likely, different strains rely on
diverse vesiculation triggers and mechanisms, which might have evolved separately [146]. The last
step of vesiculation, the fission of formed vesicles, is an active, and thus energy dependent step, but as
there is no energy source present in the periplasm, conformational changes in outer membrane proteins
are thought to be involved [133].
3.1.2. Function and Effects of OMVs
Many functions of OMVs are not yet elucidated. OMVs are generally considered to be distinct
transport system but are more refined than just the secretion of free substances into the extracellular
medium. Within OMVs, the natural cargo is protected and present at high concentrations being
comparably unaffected by diffusion. OMVs can reach their target site both between neighboring bacteria
and over long distances from the source bacteria [133]. OMVs affect their surroundings and play
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substantial roles in interspecies communication and cooperation including multicellular development,
quorum sensing, and virulence factors [147,148]. OMVs also have defensive and offensive functions,
such as lytic enzyme cargo to degrade prey bacteria for nutrition supply and for survival in complex
environments [133,149]. They are thought to be “nucleation” centers to initiate and enhance biofilm
formation [150] and also stabilize biofilms via network-like OMV chains. OMVs surrounding bacteria
can protect from viral attack by mimicking cells and absorbing viruses [151]. OMV release can also
serve as stress response to excrete misfolded, and hence potentially toxic proteins, as well as drugs
including antibiotics [143,152,153].
3.1.3. OMV Proteins
Due to the diversity of bacteria and the consequential plurality of OMVs, there are no universal
markers known for the identification of OMVs [154]. Compared to membrane proteins from other
sources, the outer membrane proteins of bacteria are not made of transmembrane α-helices but
consist of antiparallel β-barrels [155]. In contrast to mammalian EVs, bacteria show larger diversity,
interspecies differences in envelope composition, and architecture and bacterial processes, therefore,
no single mechanism of OMV export is known, making it challenging to unravel basic mechanisms
of vesicle transport. Some of the OMVs’ surface proteins are assigned to specific invasive abilities,
such as internalization into the host cell membrane [156]. To mention a few, these proteins include
invasins IpA, IpC, and IpaD, as well as outer membrane proteins from Shigella flexneri Castellani
et Chalmers aimed at enhancing cellular uptake [157]. In Escherichia coli (Migula) Castellani et
Chalmers, different outer membrane proteins (e.g., OmpA, AiL) were identified and shown to be
required for pathogenesis via host receptor interactions [158]. Another invasive bacterial protein is
ClyA, a pore forming toxin from Salmonella LigniÈres and Escherichia strains which has also been
detected in OMVs [159]. A more comprehensive overview of outer membrane and bacterial proteins
shed into OMVs can be found in recent reviews [133,156]. Once individually characterized, these OMV
proteins may be used for vaccine developments or to enhance uptake of drugs into mammalian cells
showing a potential therapeutic use [160].
3.2. Archaeal EVs
EVs from archaea can be assumed to occur in the same ubiquity as they do in the other empires
of life. They have been described for Sulfolobus Brock et al. [12,161], Ignicoccus Huber et al. [162],
Thermococcus Zillig [163], and Halorubrum McGenity et Grant [164] species and presumably more
will follow.
On the one hand, the mechanisms of EV formation by archaea are ambiguous since, in Sulfolobus
species, lipid and protein profiles between EVs and originating cell membranes revealed differences.
Additionally, the finding of ESCRT III homologues indicated that EV release was a targeted process
in Sulfolobus [161]. Moreover, the recognition of antimicrobial proteins in archaeal EVs indicates that
they play a role as defensive agents [165]. On the other hand, EVs isolated from Thermococcus showed
high similarities of proteins and lipids between originating membrane and EVs themselves. Combined
with electron microscopic images, this perception suggested Thermococcus EVs result from membrane
budding. This process is not assumed to be less specific, since minor differences, for example, in lipid
composition were detected [163]. These two mechanisms of EV release are not contradictive, as animal
EVs are known to originate either from MVBs or from membrane budding. Whether there are parallels
to EV formation machinery in eukaryote [166] or there are archaea species capable of diverse EV release
mechanisms, is still puzzling.
While EV lipids from other empires comprise phospholipids (besides other components), archaeal
EV envelopes consist of diglycerol di(tri)alkyl tetraethers, similar to membranes of archae [161,163].
Thermococcus EVs have been shown to carry DNA, prevent DNA thermodenaturation [167], and enable
the transfer of DNA and, presumably, other molecules [163,168].
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Archaeal EV proteins have not yet been the focus of research and, so far, just a few have been
identified. Among them, peptide binding receptors were found to be prominently abundant in
Thermococcus and Sulfolobus EVs [163,168]. ATP binding cassette (ABC) transporters have also been
found in Thermococcus EVs [163,168], which is remarkable because these proteins were commonly
detected in EVs from eukaryote [27,86,98]. Due to the severe differences in the proteomic profiles
of EVs from different species even within the same genus [163,168] and the extent of limited data,
it remains to be determined if universal marker proteins for archaeal EVs exist.
4. Inter-Individual, Interspecies, and Inter-Kingdom Regulation
After the observation that EV-mediated information transfer is not limited to one organism,
species or kingdoms, the one central question of EV research became, “Why can EVs overcome
kingdom boundaries?” Investigations on EV-mediated regulation processes, from mother–infant to
host–pathogen interaction, might elucidate this query (Table 2).






mother→ infant regulation [28,170,171]
elevated fungal virulence [172,173]




dietary uptake, e.g., bovine milk→ other mammals [175,176]
pathogen-host interactions, e.g., helminth↔ animal host [26,177]
elevated bacterial virulence/drug resistance beyond species
boundaries [148,153,156,174,178]
archaeal antimicrobial proteins inhibit growth of other
archaea [12,165]







dietary uptake, e.g., rice→mammal [18,189]
archaeal antimicrobial proteins inhibit bacterial growth [12,165]
In addition to mitogenic lipids and signaling proteins, sRNAs are considered to be crucial
regulatory elements in EV-mediated (inter-kingdom) communication [99]. They are able to
manipulate various biological processes, such as cell growth, differentiation, development, metabolism,
and apoptosis [19,20]. Stability and absorption of sRNA are obviously critical aspects of bioavailability
for recipient organisms or cells. In contrast to traditional persuasions on the stability of extracellular
RNA, a few studies have shown surprisingly high pH-, temperature-, and RNase-resistances for sRNA
in mammalian body fluids [26,190–194], as well as for plant sRNAs [21,80,96,195,196]. The vesicular
envelope of EVs is thought to be decisive for the enhanced sRNA stability. This assumption is strongly
underlined by the fact that severe losses of sRNA are detectable after pasteurization and homogenization
or after ultrasonic exosome depletion of bovine milk [28,175,197]. Furthermore, the envelope also
provides a vehicle for cellular uptake of the cargo, not only in the intestine [28,175,176,192,198–200].
Since EVs have been found in the milk of distinct mammals, such as pork, cow, or human,
increasing numbers of inter-individual and interspecies regulation processes are being assumed highly
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probable [28,192,201–204]. Moreover, increased serum levels of bovine milk specific sRNA were
detected in humans after consumption of cow´s milk [175]. Until today, we are lacking reliable studies
on physiological or pathological effects of ingested EVs on humans, while a broad range of such effects
is conceivable. This assumption is supported by investigations that have shown that a breastfed infant
profits from ingested milk-derived sRNAs by elevated T-cell levels and enhanced differentiation of B
cells [20,28,192,201].
Although there has been previous evidence for inter-kingdom regulation mediated by
sRNAs [205–208], the study by Zhang et al., 2012 was somehow paradigm shifting. Their finding,
that the dietary uptake of a particular plant-derived micro RNA can measurably affect the metabolism
of a mammal [189], quickly ignited increased interest in this field.
Probably, fungal cells send EVs in order to downregulate host immune response. Observations
in both human–fungus and plant–fungus interactions suggest fungal virulence to be strongly
enhanced by inter-kingdom RNA interference, enabled by sRNA containing EVs [124,172,179,181,209].
Conversely, plants send sRNA to silence fungal virulence genes, which has recently also been related
to EVs [27,91,97,106,210,211].
In the area of difficult-to-treat infections, OMVs play a major role in drug resistance because they
transfer resistance genes (DNA) between bacteria, even of different origin [148]. Many OMVs from
pathogenic bacteria were found to have surface proteins, which can readily interact with mammalian
host cells. These interaction mechanisms make OMVs a pivotal element of trans-kingdom and host-cell
communication by letting them interact in a highly specific manner [212]. OMVs have been shown to
carry PAMPs, including lipopolysaccharides, and can transfer other virulence associated factors [213].
These factors can trigger strong immune responses in host cells, while OMVs act as immunomodulators,
for example, by leading to expression of receptors on macrophages to specifically recognize the
pathogen [214]. As OMVs can help pathogenic bacteria to persist attack by the mammalian immune
system, they strongly contribute to the cause of infectious disease [174,182]. Prokaryotic pathogens
such as Bacillus anthracis Cohn [183], Helicobacter pylori (Marshall) Goodwin [184], Neisseria gonorrhoeae
(Zopf) Trevisan [185], Pseudomonas aeruginosa (Schroeter) Migula [186], and Streptococcus pneumoniae
(Klein) Chester [187], as well as eukarytotic pathogens such as Leishmania spp. Ross [215], Plasmodium
spp. Marchiafava et Celli [216], and Trichomonas vaginalis DonnÉ [217] similarly send EVs to increase
their contagiousness [188,218–220]. This phenomenon is not limited to unicellular organisms, since
helminths also modulate host immunity, as Heligosomoides polygyrus Dujardin [26] and Dicrocoelium
dendriticum Rudolphi [177].
Overall, EVs appear to be potent agents in regulation processes, crossing not only the borders
of species but rather of kingdoms or even empires. Therefore, they enhance an arms race in
host–pathogen interaction [106,180]. But do exosomes also facilitate intercellular communication
beyond the animal kingdom? Especially host–pathogen interactions imply the possibility of host-host
and pathogen-pathogen signaling, intended to improve the chance of survival on each side (Figure 4).
A better understanding of host-pathogen interactions can elucidate unknown mechanisms, and therefore
future targets, improving therapies of infectious diseases.
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Figure 4. Arms race in host–pathogen interaction. Irrespective of kingdom boundaries, the genuine
role of extracellular vesicles (EVs) appears to be bilateral. On the one hand, they were proven to have
protective properties, but, on the other hand, they also appear to contribute to the achievement of
inherent aims, like enhancing virulence on pathogens side or improving host´s immunity.
5. Conclusions
Because shedding of EVs has been found to be ubiquitous throughout all empires of life, it appears
to be evolutionarily advantageous. The abundance of homologous proteins in distinct kingdoms clearly
indicates that the release of membranous vesicles is evolutionary highly conserved. Independently from
their origin, EVs can be loaded with a wide range of drugs, including chemotherapeutic compounds,
DNA expression vectors, sRNA, and proteins such as antibodies, and have been shown in vivo to
deliver their cargo and to protect the therapeutic agent from degradation [71,102,221,222]. Because the
application of EVs can either increase or decrease the in vitro viability of cells, the bioactive cargo seems
to be responsible for the triggered effects. Lacking cytotoxic effects, edible plant-derived EV lipids are
interesting for the development of nanovectors regarding drug delivery. But since our knowledge of
the comparability of EVs from different kingdoms is limited, comprehensive EV research regarding
multiple organisms offers a better understanding of the entire field.
The EV shell is generally assumed to be crucial for the stability of sRNA or rather the complete
cargo. In animals, EVs are widely thought to facilitate intercellular communication, but we can
only speculate about the “genuine intention” of EV release. There is evidence that EV-mediated
inter-kingdom regulation is more than a random event. It seems to be more likely that cells release
EVs in order to control (remotely) or influence their environment. Possibly, plants are using EVs as
a defense strategy against invading fungi, while fungi for their part enhance their own virulence.
Therefore, the composition of membrane lipids and proteins seems to be crucial for addressing the
intended target cell, tissue, or organism. EVs consist of a complex and mutually well-coordinated
mixture of biomolecules. They can be assumed to be Janus-faced natural products and it is on us to
use this instrument in a responsible manner. Currently, we are at the beginning of a developing field
and a comprehensive view on the issue could help overseeing complex linkage. Around 20 years
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ago, a couple of researchers realized EVs to be more than tiny garbage bags. They recognized their
broad capability and kept going deeper into the unknown. As a result, we find ourselves today with
very detailed knowledge on human exosomes. Unfortunately, this knowledge cannot be transferred
one-for-one from animal EVs to other kingdoms, but those other fields can profit from well-established
methods. This will ease the way towards unpredictable findings. Thus, now, we need the same
pioneering spirit and courageousness to create a more general point of view, in order to fully exploit
the potential of the cross-linking vehicles we try to decrypt.
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Abbreviations
ABC ATP binding cassette
CHMP charged multivesicular body protein
ESCRT endosomal sorting complex required for transport
EV extracellular vesicle
ISEV International Society for Extracellular Vesicles
MISEV minimal information for studies of extracellular vesicles
MSC mesenchymal stem cell
MVB multivesicular body
OMV outer membrane vesicle
PA phosphatidic acid
PAMP pathogen-associated molecular pattern
RNAi RNA interference
SNARE soluble N-ethylmaleimide-sensitive-factor attachment receptor
sRNA small noncoding RNA
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